ReviewTrends in pharmacological sciences2013
Novel designer receptors to probe GPCR signaling and physiology.
Review in Trends in pharmacological sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 161 citations in OpenAlex.
- Astrocytic adrenergic α2 receptor contributes to the mechanisms underlying the circadian rhythmicity of seizure susceptibility.Acta pharmacologica Sinica · 2026Article
- Chemogenetic Activation of LC Noradrenergic Afferents Facilitates Cerebellar CF-PC LTD via Presynaptic αBiomolecules · 2026Article
- Synaptic plasticity in the perforant pathway drives inhibitory reorganization enhancing dentate gyrus functionality.iScience · 2026Article
- An intralayer microcircuit in the temporal association cortex underlies sensory-induced escape in mice.Nature communications · 2026Article
- Stress History Modulates Corticotropin-Releasing Factor Neurons to Establish Resilience.Biological psychiatry global open science · 2026Article
- Parasubthalamic Glutamatergic Neurons Coordinate Cardiovascular Homeostasis and Locomotion in Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Advancements in DNA-Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Neural connectivity of oxytocin receptor-expressing neurons in the nucleus accumbens and their role in social attachment.Hormones and behavior · 2025Article
- Hippocampal Inhibitory Interneuron-Specific DREADDs Treatment Alters mTORC1-4E-BP Signaling and Impairs Memory Formation.Journal of neurochemistry · 2025Article
- Advancing Neuroscience and Therapy: Insights into Genetic and Non-Genetic Neuromodulation Approaches.Cells · 2025Review
- Fasting-induced activity changes in MC3R neurons of the paraventricular nucleus of the thalamus.Life science alliance · 2024Article
- Astrocytic activation increases blood flow in the adult olfactory bulb.Molecular brain · 2024Article
- A review of cell-type specific circuit mechanisms underlying epilepsy.Acta epileptologica · 2024Review
- Article
- A non-canonical striatopallidal Go pathway that supports motor control.Nature communications · 2023Article
- In-Cell Arrestin-Receptor Interaction Assays.Current protocols · 2023Article
- Optogenetic manipulation of Gq- and Gi/o-coupled receptor signaling in neurons and heart muscle cells.eLife · 2023Article
- Review
- A non-canonical striatopallidal "Go" pathway that supports motor control.Research square · 2023Article
- Energy deficiency promotes rhythmic foraging behavior by activating neurons in paraventricular hypothalamic nucleus.Frontiers in nutrition · 2023Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Muscarinic receptor-based designer receptors have emerged as powerful novel tools to study G-protein-coupled receptor (GPCR) signaling and physiology. These new designer GPCRs, which are most frequently referred to as DREADDs (designer receptors exclusively activated by designer drug), are unable to bind acetylcholine, the endogenous muscarinic receptor agonist, but can be activated by clozapine-N-oxide (CNO), an otherwise pharmacologically inert compound, with high potency and efficacy. The various DREADDs differ primarily in their G protein coupling preference. More recently, an arrestin-biased DREADD has also been developed. The expression of DREADDs in distinct tissues or cell types has enabled researchers to study the outcome of selective stimulation of distinct GPCR (or arrestin) signaling pathways in a temporally and spatially controlled fashion in vivo. In this review, we provide an up-to-date snapshot of where this field currently stands and which important novel insights have been gained using this new technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.